| 1 |
-
Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies
-
2/6/2026 8:43:37 AM | Browse: 59 | Download: 109
|
| 2 |
-
Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients
-
12/26/2025 10:27:34 AM | Browse: 66 | Download: 292
|
| 3 |
-
Targeting gut microbiota in liver disease: A pharmacological approach for hepatic encephalopathy and beyond
-
12/5/2025 11:28:03 AM | Browse: 79 | Download: 252
|
| 4 |
-
Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends
-
12/5/2025 11:28:02 AM | Browse: 76 | Download: 180
|
| 5 |
-
Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes
-
11/27/2025 7:54:00 AM | Browse: 67 | Download: 204
|
| 6 |
-
Is higher body mass index correlated with worse clinical outcomes in acute liver failure?
-
11/12/2025 9:50:40 AM | Browse: 73 | Download: 244
|
| 7 |
-
Risk factors analysis for poor prognosis after percutaneous drainage in liver abscess patients with fatty liver
-
10/24/2025 7:36:24 AM | Browse: 163 | Download: 203
|
| 8 |
-
Myths and facts about the role of diet in metabolic dysfunctionassociated steatotic liver disease
-
8/27/2025 9:21:10 AM | Browse: 161 | Download: 553
|
| 9 |
-
Liver function improvement after human placental extract injections in patients with chronic liver disease: Thirty case reports
-
6/4/2025 7:41:49 AM | Browse: 88 | Download: 529
|
| 10 |
-
High metabolic dysfunction-associated steatotic liver disease prevalence in type 2 diabetes: Urgent need for integrated screening and lifestyle intervention
-
1/6/2025 8:47:58 AM | Browse: 105 | Download: 579
|
| 11 |
-
Effect of alpha-lipoic acid and Silybum marianum supplementation with a Mediterranean diet on metabolic dysfunction-associated steatosis
-
1/6/2025 8:47:56 AM | Browse: 101 | Download: 660
|
| 12 |
-
Predicting colorectal adenomatous polyps in patients with chronic liver disease: A novel nomogram
-
12/18/2024 7:36:04 AM | Browse: 122 | Download: 684
|
| 13 |
-
Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
-
4/24/2024 8:35:39 AM | Browse: 146 | Download: 565
|
| 14 |
-
Protein succinylation, hepatic metabolism, and liver diseases
-
3/27/2024 1:28:19 PM | Browse: 129 | Download: 534
|
| 15 |
-
Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease
-
3/14/2024 5:31:16 PM | Browse: 282 | Download: 1543
|
| 16 |
-
Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
-
9/25/2023 9:07:43 AM | Browse: 408 | Download: 1354
|
| 17 |
-
Advances in application of novel magnetic resonance imaging technologies in liver disease diagnosis
-
7/26/2023 11:55:37 AM | Browse: 325 | Download: 985
|
| 18 |
-
Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis
-
6/28/2023 7:41:03 AM | Browse: 385 | Download: 940
|
| 19 |
-
Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis
-
6/1/2023 1:04:32 PM | Browse: 297 | Download: 998
|
| 20 |
-
Fatty liver and celiac disease: Why worry?
-
5/24/2023 9:31:05 AM | Browse: 372 | Download: 1098
|
| 21 |
-
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
-
5/15/2023 3:23:22 PM | Browse: 358 | Download: 1150
|
| 22 |
-
Liver involvement in patients with COVID-19 infection: A comprehensive overview of diagnostic imaging features
-
2/6/2023 12:22:17 PM | Browse: 518 | Download: 1108
|
| 23 |
-
Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
-
1/6/2023 2:52:58 AM | Browse: 360 | Download: 815
|
| 24 |
-
In vivo recognition of bioactive substances of Polygonum multiflorum for protecting mitochondria against metabolic dysfunction-associated fatty liver disease
-
1/4/2023 5:53:02 AM | Browse: 449 | Download: 1394
|
| 25 |
-
Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis
-
9/15/2022 1:37:25 PM | Browse: 601 | Download: 1355
|
| 26 |
-
How to select the quantitative magnetic resonance technique for subjects with fatty liver: A systematic review
-
8/26/2022 9:54:52 AM | Browse: 456 | Download: 1452
|
| 27 |
-
Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease
-
8/26/2022 9:51:35 AM | Browse: 655 | Download: 1459
|
| 28 |
-
Factors early in life associated with hepatic steatosis
-
6/23/2022 2:39:01 PM | Browse: 706 | Download: 1683
|
| 29 |
-
Application of artificial intelligence in non-alcoholic fatty liver disease and viral hepatitis
-
4/29/2022 11:12:04 AM | Browse: 726 | Download: 1425
|
| 30 |
-
Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome
-
11/24/2021 9:54:22 AM | Browse: 733 | Download: 1857
|
| 31 |
-
Machine learning models for predicting non-alcoholic fatty liver disease in the general United States population: NHANES database
-
10/22/2021 1:53:28 PM | Browse: 735 | Download: 1911
|
| 32 |
-
Standard liver weight model in adult deceased donors with fatty liver: A prospective cohort study.
-
10/20/2021 7:18:39 AM | Browse: 637 | Download: 1633
|
| 33 |
-
Impact of COVID-19 on liver
-
9/16/2021 8:48:21 AM | Browse: 655 | Download: 1233
|
| 34 |
-
Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence
-
8/20/2021 9:33:19 AM | Browse: 951 | Download: 2095
|
| 35 |
-
Prevalence and risk factors of steatosis and advanced fibrosis using transient elastography in the United States’ adolescent population
-
7/23/2021 8:10:13 AM | Browse: 806 | Download: 1884
|
| 36 |
-
Non-alcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic
-
5/26/2021 9:58:01 AM | Browse: 627 | Download: 1506
|
| 37 |
-
Metabolic complications of hepatitis C virus infection
-
3/30/2021 7:03:44 AM | Browse: 796 | Download: 1696
|
| 38 |
-
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
-
12/18/2020 5:58:43 AM | Browse: 961 | Download: 2252
|
| 39 |
-
Metabolic associated fatty liver disease: Addressing a new era in liver transplantation
-
12/18/2020 5:58:43 AM | Browse: 1014 | Download: 1721
|
| 40 |
-
Fatty liver is an independent risk factor for gallbladder polyps
-
11/27/2020 9:27:48 AM | Browse: 1036 | Download: 2487
|
| 41 |
-
Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
-
11/24/2020 12:41:21 PM | Browse: 819 | Download: 2447
|
| 42 |
-
Relationship between non-alcoholic fatty liver disease and coronary heart disease
-
10/26/2020 9:59:39 AM | Browse: 879 | Download: 1794
|
| 43 |
-
Can gadoxetic acid–enhanced magnetic resonance imaging be used to avoid liver biopsy in patients with nonalcoholic fatty liver disease?
-
9/21/2020 4:02:08 PM | Browse: 786 | Download: 2620
|
| 44 |
-
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
-
8/25/2020 9:16:00 AM | Browse: 870 | Download: 2200
|
| 45 |
-
Medications in type-2 diabetics and their association with liver fibrosis
-
6/21/2020 2:15:44 PM | Browse: 857 | Download: 1890
|
| 46 |
-
Non-alcoholic fatty liver disease and Atherosclerosis at a crossroad: The overlap of a theory of change and bioinformatics
-
5/12/2020 3:08:42 AM | Browse: 987 | Download: 1803
|
| 47 |
-
Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population
-
4/23/2020 10:34:55 AM | Browse: 987 | Download: 2228
|
| 48 |
-
Single strain probiotics for dyslipidemia, fatty liver, and obesity: A systematic review and meta-analysis
-
6/30/2019 3:51:24 AM | Browse: 1437 | Download: 2790
|
| 49 |
-
C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population
-
8/27/2018 7:22:43 AM | Browse: 1298 | Download: 2249
|
| 50 |
-
Liver intravoxel incoherent motion diffusion-weighted imaging for the assessment of hepatic steatosis and fibrosis in children
-
7/19/2018 7:04:34 AM | Browse: 1342 | Download: 2795
|
